Tag Archives: biotech industry

Panelists make it personal

Panelists in the “Making it Personal” session discussed the clinical utility, comparative effectiveness implications and reimbursement for personalized medicine. Tod Klinger, PhD of XDx, Inc. asserted that we are still in the early stages of personalized medicine since there is a need to determine how to link measurements with relevant clinical information for the patient to enable decision making. Furthermore, there are many other questions that still need to be considered. Ellen Sheets, MD, of Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

The race against pandemic flu

Panelists at this morning’s Therapeutic Workshop, “Predicting a Frontrunner in the Race Against Pandemic Flu” had many valuable insights into this year’s flu pandemic, how it has compared to past pandemics, and how it will shape vaccine manufacturing in the years to come. According to Dr. Tomás Aragón, Executive Director at the Center for Infectious Disease & Emergency Readiness, “Virulence [of H1N1] is no worse than the regular flu, but a larger risk pool, consisting Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Positive results for Logical Therapeutics’ LT-NS001 vs. Naproxen clinical study

Logical Therapeutics, Inc. announced positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Endocyte awarded patent for vitamin receptor binding drug delivery conjugates

Endocyte, Inc. has been awarded a patent from the United States Patent and Trademark Office covering vitamin receptor binding anti-cancer agents. The patent, entitled “Vitamin Receptor Binding Drug Delivery Conjugates” (U.S. Patent No. 7,601,332), covers novel conjugation linkages and anti-cancer agents, including Endocyte’s EC145, which is currently in development as a potential treatment for ovarian and non-small cell lung cancers.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Oncolytics® Biotech Inc. issues 33rd U.S. patent

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) has been granted its 33rd U.S. Patent, No. 7,608,257, entitled “Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus.” The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,